- Size
- 10mg
- Purity
- 99.91%
- Formula
- C147H245N43O43S
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide, isolated from porcine small intestine by Said and Mutt in 1970 and named for the vasodilator activity that first identified it. It belongs to the secretin/glucagon superfamily and is now understood to be produced well beyond the gut — in central and peripheral neurons, in the suprachiasmatic nucleus, and by immune cells themselves.
VIP signals through the class B G-protein-coupled receptors VPAC1 and VPAC2, and with lower affinity at PAC1. Receptor engagement raises intracellular cAMP and, in immunology reviews, is described as shifting antigen-presenting cell and T-cell behaviour: reduced production of several pro-inflammatory mediators, altered chemokine expression, and effects on regulatory T-cell populations. The literature treats it as an endogenous anti-inflammatory and homeostatic mediator rather than a single-pathway drug.
Clinical investigation has concentrated on the vascular and pulmonary side of that pharmacology, including work describing reduced VIP in serum and lung tissue in primary pulmonary hypertension alongside upregulated receptor expression. Because the native peptide is short-lived in circulation, inhaled and intranasal delivery both appear in the published work — the route being an attempt to reach target tissue directly rather than a claim of superiority.
Categorised as Longevity — Compounds for cellular-ageing and immune research.For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.